DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.
Advanced or Metastatic Solid Tumors
DRUG: DCBY02
Incidence of DLTs occurring in the first 28 days following DCBY02 administration, 2 years|Frequency and severity of treatment-emergent adverse events (TEAEs), From first dose to Cycle 2 Day 8 (28 days)
Objective response rate (ORR) as determined per Investigator assessment, 1 year|Duration of response (DOR) as determined per Investigator assessment, 1 year|Disease control rate (DCR) as determined per Investigator assessment, 1 year|Progression free survival (PFS) as determined per Investigator assessment, 1 year|Overall survival (OS), 1 year|Pharmacokinetic parameters of DCBY02: maximum observed concentration (Cmax), 2 years|Pharmacokinetic parameters of DCBY02: area under the concentration-time curve (AUC), 2 years|Pharmacokinetic parameters of DCBY02: clearance (CL), 2 years|Pharmacokinetic parameters of DCBY02: volume of distribution (Vz), 2 years|Pharmacokinetic parameters of DCBY02: half-life (t1/2), 2 years|Parts 1A/2A: Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAbs) against DCBY02, 2 years
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.